The COASST study: Cost-effectiveness of albumin in severe sepsis and septic shock

Journal of Critical Care

Volumn 22, Issue 3, 2007, Pages 197-203

  Guidet, Bertrand ^a,b,c   Mosqueda, Guillermo Jasso ^d   Priol, Gaël ^d   Aegerter, Philippe ^e  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c INSERM   (France)

^d Aremis Consultants   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Albumin; Cost; Cost effectiveness; Intensive care; Sepsis; Shock

Indexed keywords

ALBUMIN;

AGED; ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE SEVERITY; FEMALE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; RESPIRATORY FAILURE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SEPSIS; SEPTIC SHOCK;

ADOLESCENT; ADULT; COLLOIDS; COST-BENEFIT ANALYSIS; FLUID THERAPY; FRANCE; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; ISOTONIC SOLUTIONS; LIFE EXPECTANCY; MIDDLE AGED; MODELS, ECONOMETRIC; PROSPECTIVE STUDIES; SEPSIS; SERUM ALBUMIN; SHOCK, SEPTIC; SODIUM CHLORIDE; SURVIVAL ANALYSIS;

EID: 34548500382     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2006.11.005     Document Type: Article

References (36)

1. Dellinger R.P., Carlet J.M., Masur H., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32 (2004) 858-873
2. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 (2001) 1368-1377
3. Vincent J.L. Fluid management: the pharmacoeconomic dimension. Crit Care 4 Suppl 2 (2000) S33-S35
4. Ernest D., Bellzberg A., and Dodek P. Distribution of normal saline and 5% albumin infusions in septic patients. Crit Care Med 27 (1999) 46-50
5. Scheingraber S., Rehm M., Sehmisch C., et al. Rapid saline infusion produces hyperchloremic acidosis in patients undergoing gynecologic surgery. Anesthesiology 90 (1999) 1265-1270
6. American Thoracic Society. Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. Am J Respir Crit Care Med 170 (2004) 1247-1259
7. Quinlan G.J., Margarson M.P., Mumby S., et al. Administration of albumin to patients with sepsis: a possible beneficial role of plasma thiol repletion. Clin Sci 95 (1998) 459-465
8. Quinlan G.J., Mumby S., Martin G.S., Bernard G.R., Gutteridge J.M., and Evans T.W. Albumin influences total plasma antioxidant capacity favourably in patients with acute lung injury. Crit Care Med 32 (2004) 755-759
9. Quinlan G.J., Martin G.S., and Evans T.W. Albumin: biochemical properties and therapeutic potential. Hepatology 41 (2005) 1211-1219
10. Gentilini P., Casini-Raggi V., and Di Fiore G. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 30 (1999) 639-645
11. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: a systematic review of randomised controlled trials. BMJ 317 (1998) 235-240
12. Wilkes M.M., and Navickis R.J. Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 135 (2001) 149-164
13. The SAFE Study investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350 (2004) 2247-2256
14. SFAR, and SRLF. Prise en charge hémodynamique du sepsis sévère (nouveau né exclu). Conférence de Consensus Commune. 13 oct. 2005. Ann Fr Anesth Reanim 25 (2006) 4-16
15. Aegerter P., Auvert B., Buonamico G., et al. Organization and quality control of a clinical database on intensive care medicine in central and suburban Paris. Rev Epidemiol Sante Publique 46 (1998) 226-237
16. LeGall J.R., Lemeshow S., and Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270 (1993) 2957-2963
17. Aegerter P., Boumendil A., Retbi A., et al. SAPS II revisited. Intensive Care Med 31 (2005) 416-423
18. McCabe W.R., and Jackson G.G. Gram-negative bacteremia. Arch Intern Med 110 (1982) 2957-2963
19. Statistiques PMSI. ATIH (2004), Bases nationales publique et privée, ATIH, France
20. Beck J.R., Kassirer J.P., and Pauker S.G. A convenient approximation of life expectancy (the ''DEALE''): I. Validation of the method. Am J Med 73 (1982) 883-888
21. Beck J.R., Pauker S.G., Gottlieb J.E., Klein K., and Kassirer J.P. A convenient approximation of life expectancy (the ''DEALE''): II. Use in medical decision-making. Am J Med 73 (1982) 889-897
22. La situation démographique en 2002-Mouvement de la population (2004), INSEE, France
23. Niskanen M., Kari A., and Halonen P. Five-year survival after intensive care-comparison of 12,180 patients with the general population. Finnish ICU Study Group. Crit Care Med 24 (1996) 1962-1967
24. Wright J.C., Plenderleith L., and Ridley S.A. Long-term survival following intensive care: subgroup analysis and comparison with the general population. Anaesthesia 58 (2003) 637-642
25. Katsaragakis S., Papadimitropoulos K., Antonakis P., Strergiopoulos S., Konstadoulakis M.M., and Androulakis G. Comparison of Acute Physiology and Chronic Health Evaluation II (APACHE II) and Simplified Acute Physiology Score II (SAPS II) scoring systems in a single Greek intensive care unit. Crit Care Med 28 (2000) 426-432
26. Newcombe R.G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 117 (1998) 873-890
27. Annane D., Aegerter P., Jars-Guincestre M.C., and Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 168 (2003) 165-172
28. Guidet B., Aegerter P., Gauzit R., Meshaka P., and Dreyfuss D. Incidence and impact of organ dysfunction associated with severe sepsis. Chest 127 (2005) 942-951
29. Adrie C., Alberti C., Chaix-Couturier C., Azoulay E., De Lassence A., Cohen Y., et al. Epidemiology and economic evaluation of severe sepsis in France: age, severity, infection site, and place of acquisition (community, hospital, or intensive care unit) as determinants of workload and cost. J Crit Care 20 (2005) 46-58
30. Brun-Buisson C., Roudot-Thoraval F., Girou E., Grenier-Sennelier C., and Durand-Zaleski I. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 29 (2003) 1464-1471
31. Edbrooke D.L., Hibbert C.L., Kingsley J.M., Smith S., Bright N.M., and Quinn J.M. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 27 (1999) 1760-1767
32. Riou Franca L., Launois R., Lelay K., Aegerter P., Bouhassira M., Meshaka P., et al. Cost-effectiveness of drotecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure. Int J Technol Assess Health Care 22 (2006) 101-108
33. Van den Hout W.B. The GAME estimate of reduced life expectancy. Med Decis Making 24 (2004) 80-88
34. Vincent J.L., Navickis R.J., and Wilkes M.M. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med 32 (2004) 2029-2038
35. Rackow E.C., Falk J.L., Fein I.A., et al. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 11 (1983) 839-850
36. Malguid C. Direction Générale du Trésor et de la Politique Économique. Analyse économique de la prévention des risques pour la santé diagnostics Prévisions et Analyses Économiques N° 71 (2005)